Clinical complications in CVID patients
| Complication . | B-cell pattern . | Total (n = 37) . | ||||
|---|---|---|---|---|---|---|
| 1 (n = 8) . | 2 (n = 4) . | 3 (n = 12) . | 4 (n = 7) . | 5 (n = 6) . | ||
| Recurrent RTI and/or ENT infections | 8 (100%) | 4 (100%) | 12 (100%) | 7 (100%) | 6 (100%) | 37 (100%) |
| Recurrent severe pneumonia* | 4 (50%) | 2 (50%) | 4 (33%) | 0 (0%) | 0 (0%) | 10 (27%) |
| Bronchiectasis | 3 (38%) | 2 (50%) | 4 (33%) | 1 (14%) | 0 (0%) | 10 (27%) |
| Autoimmune disease | 4 (50%) | 2 (50%) | 1 (8%) | 1 (14%) | 1 (17%) | 9 (24%) |
| Granulomatous inflammation | 1 (13%) | 1 (25%) | 2 (17%) | 0 (0%) | 0 (0%) | 4 (11%) |
| Splenomegaly | 6 (75%) | 1 (25%) | 3 (25%) | 0 (0%) | 0 (0%) | 10 (27%) |
| Recurrent herpes zoster | 3 (38%) | 1 (25%) | 3 (25%) | 1 (14%) | 0 (0%) | 8 (22%) |
| Recurrent lymphadenopathy | 3 (38%) | 2 (50%) | 1 (8%) | 2 (29%) | 1 (17%) | 12 (32%) |
| Complication . | B-cell pattern . | Total (n = 37) . | ||||
|---|---|---|---|---|---|---|
| 1 (n = 8) . | 2 (n = 4) . | 3 (n = 12) . | 4 (n = 7) . | 5 (n = 6) . | ||
| Recurrent RTI and/or ENT infections | 8 (100%) | 4 (100%) | 12 (100%) | 7 (100%) | 6 (100%) | 37 (100%) |
| Recurrent severe pneumonia* | 4 (50%) | 2 (50%) | 4 (33%) | 0 (0%) | 0 (0%) | 10 (27%) |
| Bronchiectasis | 3 (38%) | 2 (50%) | 4 (33%) | 1 (14%) | 0 (0%) | 10 (27%) |
| Autoimmune disease | 4 (50%) | 2 (50%) | 1 (8%) | 1 (14%) | 1 (17%) | 9 (24%) |
| Granulomatous inflammation | 1 (13%) | 1 (25%) | 2 (17%) | 0 (0%) | 0 (0%) | 4 (11%) |
| Splenomegaly | 6 (75%) | 1 (25%) | 3 (25%) | 0 (0%) | 0 (0%) | 10 (27%) |
| Recurrent herpes zoster | 3 (38%) | 1 (25%) | 3 (25%) | 1 (14%) | 0 (0%) | 8 (22%) |
| Recurrent lymphadenopathy | 3 (38%) | 2 (50%) | 1 (8%) | 2 (29%) | 1 (17%) | 12 (32%) |
RTI indicates respiratory tract infection; and ENT, ear-nose-throat.
Recurrent severe pneumonia is > 1 episode of infiltrate on the chest x-ray, hospitalization, and IV antibiotics.